{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:48:37Z","timestamp":1793382517004,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,6]]},"DOI":"10.7759\/cureus.83588","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T17:44:32Z","timestamp":1746553472000},"source":"Crossref","is-referenced-by-count":1,"title":["Progressive Supranuclear Palsy: Clinical Features and Neuroimaging in a Case Series"],"prefix":"10.7759","author":[{"given":"Favio M.","family":"Fimbres-Laborin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Carrillo-Mezo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Lopez de la Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Catherine","family":"Boll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00541-5","article-title":"Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies","volume":"17","author":"Stamelou M","year":"2021","unstructured":"Stamelou M, Respondek G, Giagkou N, Whitwell JL, Kovacs GG, H\u00f6glinger GU. Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. Nat Rev Neurol. 2021, 17:601-20. 10.1038\/s41582-021-00541-5","journal-title":"Nat Rev Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2018.1489241","article-title":"The diagnosis of progressive supranuclear palsy: current opinions and challenges","volume":"18","author":"Ali F","year":"2018","unstructured":"Ali F, Josephs K. The diagnosis of progressive supranuclear palsy: current opinions and challenges. Expert Rev Neurother. 2018, 18:603-16. 10.1080\/14737175.2018.1489241","journal-title":"Expert Rev Neurother"},{"key":"ref3","article-title":"Clinical diagnosis of atypical Parkinsonisms (Article in Spanish)","volume":"18","author":"S\u00e1nchez-Jord\u00e1n A","year":"2017","unstructured":"S\u00e1nchez-Jord\u00e1n A, Medina-Rioja R, Boll-Woehrlen MC. Clinical diagnosis of atypical Parkinsonisms (Article in Spanish). Rev Mex Neuroci. 2017, 18:88-99.","journal-title":"Rev Mex Neuroci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1964.00460160003001","article-title":"Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia","volume":"10","author":"ST JC","year":"1964","unstructured":"ST JC, RI JC, OL J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964, 10:333-59. 10.1001\/archneur.1964.00460160003001","journal-title":"Arch Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1229491","article-title":"Clinical features of progressive supranuclear palsy","volume":"15","author":"Wen Y","year":"2023","unstructured":"Wen Y, Yang Q, Jiao B, et al.. Clinical features of progressive supranuclear palsy. Front Aging Neurosci. 2023, 15:1229491. 10.3389\/fnagi.2023.1229491","journal-title":"Front Aging Neurosci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria","volume":"32","author":"H\u00f6glinger GU","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M, et al.. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord. 2017, 32:853-64. 10.1002\/mds.26987","journal-title":"Mov Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2024.101753","article-title":"Progressive supranuclear palsy: neuropathology, clinical presentation, diagnostic challenges, management, and emerging therapies","volume":"70","author":"DeRosier F","year":"2024","unstructured":"DeRosier F, Hibbs C, Alessi K, Padda I, Rodriguez J, Pradeep S, Parmar MS. Progressive supranuclear palsy: neuropathology, clinical presentation, diagnostic challenges, management, and emerging therapies. Dis Mon. 2024, 70:101753. 10.1016\/j.disamonth.2024.101753","journal-title":"Dis Mon"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2020.04.014","article-title":"Progressive supranuclear palsy: advances in diagnosis and management","volume":"73","author":"Coughlin DG","year":"2020","unstructured":"Coughlin DG, Litvan I. Progressive supranuclear palsy: advances in diagnosis and management. Parkinsonism Relat Disord. 2020, 73:105-16. 10.1016\/j.parkreldis.2020.04.014","journal-title":"Parkinsonism Relat Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint16010001","article-title":"Planimetric and volumetric brainstem MRI markers in progressive supranuclear palsy, multiple system atrophy, and corticobasal syndrome. A systematic review and meta-analysis","volume":"16","author":"Brinia ME","year":"2023","unstructured":"Brinia ME, Kapsali I, Giagkou N, Constantinides VC. Planimetric and volumetric brainstem MRI markers in progressive supranuclear palsy, multiple system atrophy, and corticobasal syndrome. A systematic review and meta-analysis. Neurol Int. 2023, 16:1-19. 10.3390\/neurolint16010001","journal-title":"Neurol Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27964","article-title":"The progressive supranuclear palsy clinical deficits scale","volume":"35","author":"Piot I","year":"2020","unstructured":"Piot I, Schweyer K, Respondek G, et al.. The progressive supranuclear palsy clinical deficits scale. Mov Disord. 2020, 35:650-61. 10.1002\/mds.27964","journal-title":"Mov Disord"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.04.005","article-title":"The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative Parkinsonism","volume":"54","author":"Mueller C","year":"2018","unstructured":"Mueller C, Hussl A, Krismer F, et al.. The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative Parkinsonism. Parkinsonism Relat Disord. 2018, 54:90-4. 10.1016\/j.parkreldis.2018.04.005","journal-title":"Parkinsonism Relat Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27038","article-title":"Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be?","volume":"32","author":"Whitwell JL","year":"2017","unstructured":"Whitwell JL, H\u00f6glinger GU, Antonini A, et al.. Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be?. Mov Disord. 2017, 32:955-71. 10.1002\/mds.27038","journal-title":"Mov Disord"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23529","article-title":"Accuracy of magnetic resonance Parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease","volume":"26","author":"Morelli M","year":"2011","unstructured":"Morelli M, Arabia G, Salsone M, et al.. Accuracy of magnetic resonance Parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease. Mov Disord. 2011, 26:527-33. 10.1002\/mds.23529","journal-title":"Mov Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.07.016","article-title":"A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson's disease","volume":"54","author":"Quattrone A","year":"2018","unstructured":"Quattrone A, Morelli M, Nigro S, et al.. A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson's disease. Parkinsonism Relat Disord. 2018, 54:3-8. 10.1016\/j.parkreldis.2018.07.016","journal-title":"Parkinsonism Relat Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-321354","article-title":"Midbrain MRI assessments in progressive supranuclear palsy subtypes","volume":"91","author":"Picillo M","year":"2020","unstructured":"Picillo M, Tepedino MF, Abate F, et al.. Midbrain MRI assessments in progressive supranuclear palsy subtypes. J Neurol Neurosurg Psychiatry. 2020, 91:98-103. 10.1136\/jnnp-2019-321354","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12070949","article-title":"Magnetic resonance planimetry in the differential diagnosis between Parkinson's disease and progressive supranuclear palsy","volume":"12","author":"Quattrone A","year":"2022","unstructured":"Quattrone A, Morelli M, Bianco MG, et al.. Magnetic resonance planimetry in the differential diagnosis between Parkinson's disease and progressive supranuclear palsy. Brain Sci. 2022, 12:949. 10.3390\/brainsci12070949","journal-title":"Brain Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2017.05.002","article-title":"Magnetic resonance Parkinsonism Index and midbrain to pons ratio: which index better distinguishes progressive supranuclear palsy patients with a low degree of diagnostic certainty from patients with Parkinson's Disease?","volume":"41","author":"Nigro S","year":"2017","unstructured":"Nigro S, Morelli M, Arabia G, et al.. Magnetic resonance Parkinsonism Index and midbrain to pons ratio: which index better distinguishes progressive supranuclear palsy patients with a low degree of diagnostic certainty from patients with Parkinson's Disease?. Parkinsonism Relat Disord. 2017, 41:31-6. 10.1016\/j.parkreldis.2017.05.002","journal-title":"Parkinsonism Relat Disord"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29527","article-title":"Brain MRI in progressive supranuclear palsy with Richardson's syndrome and variant phenotypes","volume":"38","author":"Wattjes MP","year":"2023","unstructured":"Wattjes MP, Huppertz HJ, Mahmoudi N, et al.. Brain MRI in progressive supranuclear palsy with Richardson's syndrome and variant phenotypes. Mov Disord. 2023, 38:1891-900. 10.1002\/mds.29527","journal-title":"Mov Disord"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.15944","article-title":"Cerebrospinal fluid and blood serum biomarkers in neurodegenerative proteinopathies. A prospective, open, cross-correlation study","volume":"167","author":"Kon\u00ed\u010dkov\u00e1 D","year":"2023","unstructured":"Kon\u00ed\u010dkov\u00e1 D, Men\u0161\u00edkov\u00e1 K, Kl\u00ed\u010dov\u00e1 K, et al.. Cerebrospinal fluid and blood serum biomarkers in neurodegenerative proteinopathies. A prospective, open, cross-correlation study. J Neurochem. 2023, 167:168-82.","journal-title":"J Neurochem"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/342726-progressive-supranuclear-palsy-clinical-features-and-neuroimaging-in-a-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T17:44:33Z","timestamp":1746553473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/342726-progressive-supranuclear-palsy-clinical-features-and-neuroimaging-in-a-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.83588","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,6]]}}}